Makale detayı · 2009 · article
Effect of bevacizumab on corneal neovascularization in experimental rabbit model
Veri kaynağı ayrımı
- YÖKSİSYÖKSİS makale kaydı
- YÖKSİS dergi adıClinical & Experimental Ophthalmology
- Katalog eşleşmesi (ISSN)Clinical and Experimental Ophthalmology
- OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
- Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)
Özet
PURPOSE: To investigate the effect of bevacizumab in an experimental rabbit model of corneal neovascularization. METHODS: The right eyes of 24 white New Zealand rabbits were included in a corneal neovascularization model using alkaline burn. They were divided into four groups. Topical bevacizumab was installed three times daily in group 1, 5 mg bevacizumab subconjunctivally every 2 days in group 2, 10 mg bevacizumab subconjunctivally every 2 days in group 3 and 0.2 cc of normal saline in the same way in group 4 (control group). All eyes were treated for 7 days. Then the animals were killed and corneal specimens sent for histopathological analysis. Tear film and aqueous humour samples were obtained to assess vascular endothelial growth factor (VEGF) levels. RESULTS: Seven days after topical bevacizumab treatment the neovascular index in group 1 was lower than that in the control group (P = 0.028). In groups 2 and 3 the neovascular index was lower 2 days after subconjunctival bevacizumab treatment than that in control group (P = 0.009 and P = 0.009, respectively). In the control group the VEGF level in aqueous humour increased by 66% from day 7 to 14. In groups 1-3 it decreased by 49.80%, 70.20% and 76.44%, respectively (P = 0.043). The VEGF level in tear film of the control group increased by 35.23% from day 7 to 14, which was not significant (P = 0.893), while in groups 1-3 it decreased by 57.26%, 34.59% and 67.97%, respectively, which was only significant in groups 1 and 3 (P = 0.043). CONCLUSIONS: Subconjunctival 5 mg/mL bevacizumab is effective in reducing corneal neovascularization in animal models and in reducing VEGF levels. Further research is needed to assess the potential side effects and minimal effective dose.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
32atıfOpenAlex · cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 14 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- 2014 Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularizationAtıf 29 · OpenAlex
- 2015 Inhibitory Effect of Sub conjunctival Tocilizumab on Alkali Burn Induced Corneal Neovascularization in RatsAtıf 24 · OpenAlex
- 2015 Inhibitory Effect of Sub conjunctival Tocilizumab on Alkali Burn Induced Corneal Neovascularization in RatsAtıf 24 · OpenAlex
- 2015 Inhibitory Effect of Sub conjunctival Tocilizumab on Alkali Burn Induced Corneal Neovascularization in RatsAtıf 24 · OpenAlex
- 2015 Inhibitory Effect of Sub conjunctival Tocilizumab on Alkali Burn Induced Corneal Neovascularization in RatsAtıf 24 · OpenAlex
- 2014 Inhibitory Effect of Sub-conjunctival Tocilizumab on Alkali Burn Induced Corneal Neovascularization in RatsAtıf 24 · OpenAlex
- 2014 Inhibitory Effect of Sub-conjunctival Tocilizumab on Alkali Burn Induced Corneal Neovascularization in RatsAtıf 24 · OpenAlex
- 2013 Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat modelAtıf 19 · OpenAlex
- 2013 Topical and subconjunctival ranibizumab lucentis for corneal neovascularization in experimental rat modelAtıf 19 · OpenAlex
- 2022 The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularizationAtıf 17 · OpenAlex